Exploring The Future of NF1-PN Management

EP: 1.Genetic And Molecular Mechanisms of NF1

EP: 2.Diagnosis, Epidemiology, And Risk Factors Of NF1-PN

EP: 3.Hallmark Symptoms and Clinical Features of NF1-PN

EP: 4.Quality of Life in Patients With NF1-PN

EP: 5.Key Clinical Considerations in NF1-PN Management

EP: 6.Unmet Needs of Patients Living With NF1-PN

EP: 7.Main Goals in the Management of NF1-PN

EP: 8.Rationale for MEK Inhibitors and Surgery

EP: 9.Selumetinib as a Therapeutic Option for NF1-PN

EP: 10.Examining Combination Therapy In NF1-PN

EP: 11.Barriers to Optimal NF1-PN Care for Patients

EP: 12.Lessons From Previously Used Therapies In NF1-PN

EP: 13.ReNeu Trial & Efficacy of Mirdametinib in NF1-PN

EP: 14.Mirdametinib as a Therapy for Patients With NF1-PN

EP: 15.The Role of Biomarkers in NF1-PN Care

EP: 16.Guideline Recommendations for Newer NF1-PN Therapies

EP: 17.Potential of Gene Therapy for NF1-PN

Now Viewing

EP: 18.Exploring The Future of NF1-PN Management

Summary for Physicians

Future of NF1-PN Management
The management of neurofibromatosis type 1–associated plexiform neurofibromas (NF1-PN) is likely to evolve significantly over the next few years with advances in targeted therapies, gene therapies, and personalized medicine. As our understanding of the RAS/MAPK pathway and other molecular drivers deepens, we can expect more effective and tailored treatments, such as combination therapies and gene editing techniques. Early detection through biomarkers and improved imaging will allow for earlier intervention, potentially preventing tumor progression and improving long-term outcomes.

Additionally, long-term disease management will increasingly focus on quality of life, with an emphasis on psychosocial support, pain management, and functional rehabilitation. Advances in precision medicine will enable clinicians to better identify the right therapies for each patient, improving efficacy while minimizing adverse effects.